Literature DB >> 27015744

In silico modeling of the dynamics of low density lipoprotein composition via a single plasma sample.

Martin Jansen1, Peter Pfaffelhuber2, Michael M Hoffmann3, Gerhard Puetz3, Karl Winkler3.   

Abstract

Lipoproteins play a key role in the development of CVD, but the dynamics of lipoprotein metabolism are difficult to address experimentally. This article describes a novel two-step combined in vitro and in silico approach that enables the estimation of key reactions in lipoprotein metabolism using just one blood sample. Lipoproteins were isolated by ultracentrifugation from fasting plasma stored at 4°C. Plasma incubated at 37°C is no longer in a steady state, and changes in composition may be determined. From these changes, we estimated rates for reactions like LCAT (56.3 µM/h), β-LCAT (15.62 µM/h), and cholesteryl ester (CE) transfer protein-mediated flux of CE from HDL to IDL/VLDL (21.5 µM/h) based on data from 15 healthy individuals. In a second step, we estimated LDL's HL activity (3.19 pools/day) and, for the very first time, selective CE efflux from LDL (8.39 µM/h) by relying on the previously derived reaction rates. The estimated metabolic rates were then confirmed in an independent group (n = 10). Although measurement uncertainties do not permit us to estimate parameters in individuals, the novel approach we describe here offers the unique possibility to investigate lipoprotein dynamics in various diseases like atherosclerosis or diabetes.
Copyright © 2016 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  lecithin:cholesterol acyltransferase; lipase/hepatic; lipid transfer proteins; lipoproteins/kinetics; low density lipoprotein/metabolism

Mesh:

Substances:

Year:  2016        PMID: 27015744      PMCID: PMC4847624          DOI: 10.1194/jlr.M058446

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  44 in total

1.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk.

Authors:  M A Austin; M C King; K M Vranizan; R M Krauss
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

2.  Endogenously labeled low density lipoprotein triglyceride and apoprotein B kinetics.

Authors:  C Malmendier; M Berman
Journal:  J Lipid Res       Date:  1978-11       Impact factor: 5.922

3.  A new labeling approach using stable isotopes to study in vivo plasma cholesterol metabolism in humans.

Authors:  K Ouguerram; M Krempf; C Maugeais; P Maugère; D Darmaun; T Magot
Journal:  Metabolism       Date:  2002-01       Impact factor: 8.694

4.  Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules.

Authors:  Xiayang Qiu; Anil Mistry; Mark J Ammirati; Boris A Chrunyk; Ronald W Clark; Yang Cong; Jeffrey S Culp; Dennis E Danley; Thomas B Freeman; Kieran F Geoghegan; Matthew C Griffor; Steven J Hawrylik; Cheryl M Hayward; Preston Hensley; Lise R Hoth; George A Karam; Maruja E Lira; David B Lloyd; Katherine M McGrath; Kim J Stutzman-Engwall; Ann K Subashi; Timothy A Subashi; John F Thompson; Ing-Kae Wang; Honglei Zhao; Andrew P Seddon
Journal:  Nat Struct Mol Biol       Date:  2007-01-21       Impact factor: 15.369

5.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

6.  Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Authors:  Laura K Potter; Dennis L Sprecher; Max C Walker; Frank L Tobin
Journal:  J Lipid Res       Date:  2009-03-11       Impact factor: 5.922

7.  Inhibition of cholesteryl ester transfer protein activity by monoclonal antibody. Effects on cholesteryl ester formation and neutral lipid mass transfer in human plasma.

Authors:  F T Yen; R J Deckelbaum; C J Mann; Y L Marcel; R W Milne; A R Tall
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

8.  Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

Authors:  Karl Winkler; Thomas Konrad; Stefanie Füllert; Isolde Friedrich; Ramadan Destani; Manfred W Baumstark; Kristin Krebs; Heinrich Wieland; Winfried März
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

9.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

10.  Analysis of the selective uptake of the cholesteryl ester of human intermediate density lipoproteins by HepG2 cells.

Authors:  L Brissette; L Falstrault
Journal:  Biochim Biophys Acta       Date:  1994-06-23
View more
  2 in total

1.  A mathematical model to estimate cholesterylester transfer protein (CETP) triglycerides flux in human plasma.

Authors:  Martin Jansen; Gerhard Puetz; Michael M Hoffmann; Karl Winkler
Journal:  BMC Syst Biol       Date:  2019-01-22

2.  LDL retention time in plasma can be -based on causation- estimated by the lipid composition of LDL and other lipoproteins.

Authors:  Martin Jansen; Christine Contini
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.